CD4 and neoplasm: Taken together, ibrutinib-mediated inhibition of BTK in TAMs, MDSCs, DCs and B cells indirectly promote anti-tumor immunity by augmenting TH1 CD4 T cell response and increasing the infiltration of CD8 cytotoxic T cells and effector B cells into the TME (24, 69, 74, 77, 80, 84, 93).